How does erdafitinib stop bladder cancer from growing?
Erdafitinib blocks a protein called FGFR that tells cancer cells to multiply. About 36% of patients with FGFR-mutated bladder tumors see their cancer shrink, and some stay cancer-free for years [1].
In the BLC4 trial, 99 patients with advanced bladder cancer took erdafitinib. Thirty-six percent had their tumors shrink by at least 30%, and the drug extended survival by 4.7 months compared to chemotherapy. These numbers come straight from the FDA approval data and The New England Journal of Medicine [1].
Inside your body, erdafitinib enters cancer cells and glues itself to the FGFR protein, like a key jamming a lock. This stops the cancer cell from receiving the 'grow' signal. Your healthy cells have FGFR too, but cancer cells depend on it much more heavily, so the drug hits tumors harder than normal tissue [3].
The catch: erdafitinib only works if your tumor has an FGFR mutation. About 15–20% of bladder cancers carry this mutation. Your oncologist must run a genetic test first. If your tumor doesn't have FGFR changes, erdafitinib won't help, and you'd need a different drug [1].
Ask your oncologist: 'Has my tumor been tested for FGFR mutations?' If yes and it's positive, erdafitinib is worth discussing. If no, request the test before your next visit—it takes 1–2 weeks and determines whether this drug is right for you.